Related Experiment Video

Updated: Jul 13, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells

Paul N Meyer1, Shantanu Roychowdhury, Ameet R Kini

  • 1Loyola University Medical Center, Department of Pathology, 2160 S First Avenue, Maywood, IL 60153, USA.

Leukemia Research
|July 10, 2007
PubMed

Insights

A novel heat shock protein inhibitor, 17AAG, effectively induces apoptosis in acute promyelocytic leukemia (APL) cell lines. This agent offers a potential new therapeutic strategy for APL patients resistant to standard treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Acute promyelocytic leukemia (APL) is a subtype of leukemia.
  • Resistance to standard therapy, such as all-trans retinoic acid (ATRA), is a clinical challenge in APL.
  • Heat shock proteins (HSPs), particularly HSP90, are implicated in cancer cell survival and drug resistance.

Purpose of the Study:

  • To investigate the efficacy of a novel HSP90 inhibitor, 17AAG, against established APL cell lines.
  • To elucidate the mechanism of action of 17AAG in APL cells.
  • To evaluate the potential of HSP90 inhibition as a therapeutic strategy for APL.

Main Methods:

  • Treatment of APL cell lines (NB4 and R1) with 17AAG.
  • Assessment of apoptosis induction and differentiation markers.
  • Analysis of pro-apoptotic (bax) and anti-apoptotic (bcl-2) protein expression.

Main Results:

  • 17AAG induced apoptosis in both ATRA-sensitive (NB4) and ATRA-resistant (R1) APL cell lines after 72 hours.
  • Apoptosis occurred independently of differentiation, suggesting a distinct mechanism from ATRA.
  • 17AAG treatment led to decreased expression of both bax and bcl-2 proteins.

Conclusions:

  • 17AAG demonstrates potent anti-leukemic activity by inducing apoptosis in APL cells.
  • The mechanism of 17AAG-induced apoptosis differs from ATRA, offering an alternative therapeutic pathway.
  • Targeting HSP90 with agents like 17AAG holds promise for APL patients refractory to conventional therapies.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...